Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 30547 | 136 | 30.2 | 64% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1443 | 7316 | EQ 5D//HEALTH TECHNOLOGY ASSESSMENT//INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | IST MED INTERNA VASCOLARE | Address | 2 | 67% | 1% | 2 |
| 2 | AALENS MODEL | Author keyword | 1 | 50% | 1% | 1 |
| 3 | ADJUSTED SURVIVAL | Author keyword | 1 | 50% | 1% | 1 |
| 4 | ADJUSTED SURVIVAL CURVES | Author keyword | 1 | 50% | 1% | 1 |
| 5 | CARDIOLEMORY OUTCOMES | Address | 1 | 50% | 1% | 1 |
| 6 | DIRECT ADJUSTMENT | Author keyword | 1 | 50% | 1% | 1 |
| 7 | EARLY TERMINATION OF TRIALS | Author keyword | 1 | 50% | 1% | 1 |
| 8 | EXTRAPOLATION MODEL | Author keyword | 1 | 50% | 1% | 1 |
| 9 | PHARMACEUTICAL SUPPORT | Author keyword | 1 | 50% | 1% | 1 |
| 10 | WEIGHTED KAPLAN MEIER | Author keyword | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | AALENS MODEL | 1 | 50% | 1% | 1 | Search AALENS+MODEL | Search AALENS+MODEL |
| 2 | ADJUSTED SURVIVAL | 1 | 50% | 1% | 1 | Search ADJUSTED+SURVIVAL | Search ADJUSTED+SURVIVAL |
| 3 | ADJUSTED SURVIVAL CURVES | 1 | 50% | 1% | 1 | Search ADJUSTED+SURVIVAL+CURVES | Search ADJUSTED+SURVIVAL+CURVES |
| 4 | DIRECT ADJUSTMENT | 1 | 50% | 1% | 1 | Search DIRECT+ADJUSTMENT | Search DIRECT+ADJUSTMENT |
| 5 | EARLY TERMINATION OF TRIALS | 1 | 50% | 1% | 1 | Search EARLY+TERMINATION+OF+TRIALS | Search EARLY+TERMINATION+OF+TRIALS |
| 6 | EXTRAPOLATION MODEL | 1 | 50% | 1% | 1 | Search EXTRAPOLATION+MODEL | Search EXTRAPOLATION+MODEL |
| 7 | PHARMACEUTICAL SUPPORT | 1 | 50% | 1% | 1 | Search PHARMACEUTICAL+SUPPORT | Search PHARMACEUTICAL+SUPPORT |
| 8 | WEIGHTED KAPLAN MEIER | 1 | 50% | 1% | 1 | Search WEIGHTED+KAPLAN+MEIER | Search WEIGHTED+KAPLAN+MEIER |
| 9 | WEIGHTED MEAN SURVIVAL TEST | 1 | 50% | 1% | 1 | Search WEIGHTED+MEAN+SURVIVAL+TEST | Search WEIGHTED+MEAN+SURVIVAL+TEST |
| 10 | NUMBER AT RISK | 0 | 33% | 1% | 1 | Search NUMBER+AT+RISK | Search NUMBER+AT+RISK |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | CURE TRIAL | 2 | 43% | 2% | 3 |
| 2 | EVALUATION HOPE | 1 | 100% | 1% | 2 |
| 3 | REDUCING ATHEROTHROMBOTIC EVENTS | 1 | 100% | 1% | 2 |
| 4 | TERM COST EFFECTIVENESS | 1 | 21% | 3% | 4 |
| 5 | CAROTID ULTRASOUND CHANGES | 1 | 50% | 1% | 1 |
| 6 | STATUTORY HEALTH INSURANCE | 0 | 20% | 1% | 2 |
| 7 | HIGH ATHEROTHROMBOTIC RISK | 0 | 33% | 1% | 1 |
| 8 | OCCLUSIVE VASCULAR EVENTS | 0 | 33% | 1% | 1 |
| 9 | TERM CLOPIDOGREL THERAPY | 0 | 33% | 1% | 1 |
| 10 | TERM COST | 0 | 33% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Review of Case-Mix Corrected Survival Curves | 2012 | 4 | 23 | 43% |
| Cost-effectiveness of oral antiplatelet agents-current and future perspectives | 2011 | 5 | 52 | 33% |
| Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease | 2007 | 11 | 34 | 38% |
| Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations | 2013 | 2 | 71 | 24% |
| Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome, Transient Ischemic Attack, and Noncardioembolic Stroke in an Era of Cost Containment | 2012 | 0 | 56 | 38% |
| Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome | 2014 | 0 | 50 | 24% |
| Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness | 2004 | 11 | 37 | 14% |
| Expensive care - a rationale for economic evaluations in intensive care | 2010 | 3 | 26 | 4% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | IST MED INTERNA VASCOLARE | 2 | 67% | 1.5% | 2 |
| 2 | CARDIOLEMORY OUTCOMES | 1 | 50% | 0.7% | 1 |
| 3 | YUXI PEOPLES HOSP | 1 | 50% | 0.7% | 1 |
| 4 | HLTH SYST PERFORMANCE | 0 | 33% | 0.7% | 1 |
| 5 | MID AMER BRAIN STROKE | 0 | 33% | 0.7% | 1 |
| 6 | THORAC SURG DIS OESOPHAGUS | 0 | 33% | 0.7% | 1 |
| 7 | OUTCOMES HLTH ECON | 0 | 15% | 1.5% | 2 |
| 8 | CREMS | 0 | 25% | 0.7% | 1 |
| 9 | GRP RECH ANAL SYST SOINS HOSP | 0 | 25% | 0.7% | 1 |
| 10 | NEUROL CLIN POLICLIN | 0 | 25% | 0.7% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000173029 | MRC TRIAL//ABORAT PREVENT TREATMENT CARDIOVASC DIS//CLIN EPIDEMIOL HLTH CARE PROGRAM MED |
| 2 | 0.0000165301 | CLOPIDOGREL//PRASUGREL//TICAGRELOR |
| 3 | 0.0000151771 | COST EFFECTIVENESS ANALYSIS//BRIGHAM WOMENS FAULKNER NEUROL//OPTIMAL TRIAL DESIGN |
| 4 | 0.0000145512 | TRANSIENT ISCHEMIC ATTACK//ABCD2 SCORE//TIA |
| 5 | 0.0000097144 | FRICTION COSTS//PRODUCTIVITY COSTS//COST OF SMOKING |
| 6 | 0.0000092943 | NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME//TERRENCE DONNELLY HEART//CANADIAN HEART |
| 7 | 0.0000090518 | TURKISH SOC CARDIOL//EXECUTIVE STRESS//MINNESOTA CODING |
| 8 | 0.0000079332 | TELESTROKE//STROKE UNIT//STROKE UNITS |
| 9 | 0.0000068219 | ACT STUDY//ASPIRIN DOSE//ANTIOXIDANT DEFENSE MECHANISM |
| 10 | 0.0000067660 | VASCULAR SURGERY PROCEDURES//ARTERIOSCLEROSIS SURGERY//BOA TRIAL OFF |